(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology...
Stats | |
---|---|
Šios dienos apimtis | 164 828 |
Vidutinė apimtis | 94 440 |
Rinkos kapitalizacija | 38.18M |
EPS | $-0.120 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-07-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.190 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0110 (1.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
INSIDER POWER |
---|
77.02 |
Last 100 transactions |
Buy: 4 191 625 | Sell: 429 500 |
Tūris Koreliacija
Cytosorbents Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TELA | 0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cytosorbents Corp Koreliacija - Valiuta/Žaliavos
Cytosorbents Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $36.35M |
Bruto pelnas: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2023 |
Pajamos: | $36.35M |
Bruto pelnas: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2022 |
Pajamos: | $29.36M |
Bruto pelnas: | $15.40M (52.47 %) |
EPS: | $-0.750 |
FY | 2021 |
Pajamos: | $43.17M |
Bruto pelnas: | $32.12M (74.41 %) |
EPS: | $-0.570 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.